What is Summit Therapeutics?
Summit Therapeutics is an international biopharmaceutical enterprise headquartered in Cambridge, UK, dedicated to the discovery and development of innovative medicines. The company maintains a primary focus on Duchenne muscular dystrophy, a severe genetic disorder that requires sophisticated, targeted therapeutic solutions. By leveraging advanced research methodologies, Summit Therapeutics operates at the intersection of biotechnology and clinical medicine, aiming to bridge the gap between laboratory discovery and patient-centric outcomes. Its market position is defined by its commitment to addressing unmet medical needs through rigorous scientific inquiry and strategic collaboration within the global life sciences ecosystem.
How much funding has Summit Therapeutics raised?
Summit Therapeutics has raised a total of $1.2B across 4 funding rounds:
Stock Offering
$34.2M
Share Placement
$200M
Stock/Share Issuance
$500M
Stock/Share Issuance
$500M
Stock Issuance/Offering (2015): $34.2M, investors not publicly disclosed
Share Placement (2024): $200M, investors not publicly disclosed
Stock/Share Issuance (2025): $500M supported by Akeso
Stock/Share Issuance (2025): $500M featuring Akeso
Key Investors in Summit Therapeutics
Akeso
Akeso, Inc is a pioneering biopharmaceutical company focused on the research and development of innovative antibody drugs for major diseases such as cancer, autoimmune disorders, and metabolic diseases. The company utilizes its proprietary ACE Platform to address unmet clinical needs through advanced antibody technologies.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Summit Therapeutics?
With the successful closure of this major strategic investment, Summit Therapeutics is expected to prioritize the advancement of its lead candidates through late-stage clinical trials. The capital will likely be deployed to scale manufacturing processes, enhance regulatory engagement, and potentially broaden the scope of its therapeutic platform. As the company navigates the complexities of drug development, the focus will remain on achieving key clinical milestones that validate its proprietary technology. Investors and industry observers will be monitoring the firm's ability to translate this financial backing into tangible therapeutic breakthroughs, which remain the ultimate benchmark for success in the competitive biopharmaceutical landscape.
See full Summit Therapeutics company page
